ライフサイエンスコーパス: non-inferior

1 sis that using rituximab would be clinically non-inferior and cheaper compared with TNF inhibitor tre

2 t with 8 Gy in a single fraction seems to be non-inferior and less toxic than 20 Gy in multiple fract

3 .9% vs. 26.1%) that resulted in a shock were non-inferior and lower in the EMPIRIC arm compared to th

4 4F-PCC is non-inferior and superior to plasma for rapid INR revers

5 Aflibercept was non-inferior and superior to PRP in both the modified in

6 Zoledronic acid was non-inferior and superior to risedronate for increase of

7 hort schedules for mOPV1 and bOPV elicited a non-inferior antibody response compared with the bOPV st

8 8.4 to 1.5), indicating that raltegravir was non-inferior, but not superior, to NRTIs.

9 ix-PT and that this would lead to at least a non-inferior clinical outcome compared with monitoring w

10 Bivalent OPV was non-inferior compared with monovalent OPV (p=0.21).

11 A once daily raltegravir 1200 mg regimen was non-inferior compared with raltegravir 400 mg twice dail

12 n this phase 3 study, we aimed to assess the non-inferior efficacy and pharmacokinetic equivalence of

13 In this study, we show that CT-P10 exhibits non-inferior efficacy and pharmacokinetic equivalence to

14 INTERPRETATION: The non-inferior efficacy and similar safety profile of the

15 al failures, a favourable safety profile and non-inferior efficacy compared with efavirenz means that

16 and raltegravir (raltegravir-group) provided non-inferior efficacy to ritonavir-boosted lopinavir and

17 LSTENT plus FilterWire embolic protection is non-inferior (equivalent or better than) to CEA at 1-yea

18 containing tenofovir disoproxil fumarate was non-inferior for maintenance of viral suppression and le

19 Edoxaban, an oral factor Xa inhibitor, is non-inferior for prevention of stroke and systemic embol

20 single bolus injection and was statistically non-inferior from two bolus injections spaced 1 month ap

21 e related to HPV 31, 33, 45, 52, and 58, and non-inferior HPV 6, 11, 16, and 18 antibody responses wh

22 Treatment with OSC alone was considered non-inferior if it was no more than 7 QALY days worse th

23 On-demand treatment was considered non-inferior if the upper limit of the one-sided 95 % co

24 three-dose prime-only PCV schedule provided non-inferior immunogenicity in early infancy and superio

25 abine, and tenofovir disoproxil fumarate was non-inferior in maintaining viral suppression and was we

26 ther efficacy, safety, and tolerability were non-inferior in patients switched to a regimen containin

27 ates against polioviruses types 1 and 3 were non-inferior in sequential schedules containing IPV and

28 We investigated whether simeprevir is non-inferior in terms of efficacy to telaprevir, each in

29 itabine instead of cyclophosphamide would be non-inferior in terms of patients' outcomes and would im

30 HPV 6, 11, 16, and 18 GMTs were non-inferior in the 9vHPV versus qHPV group from month 1

31 The time to first all-cause shock was non-inferior in the EMPIRIC arm (hazard ratio = 0.95, 90

32 dpoints of superior vasomotor reactivity and non-inferior late luminal loss for the Absorb bioresorba

33 Discontinuous treatment was neither non-inferior nor inferior to continuous treatment (-1.63

34 For BCVA, bevacizumab was neither non-inferior nor inferior to ranibizumab (mean differenc

35 r severe aortic regurgitation, TAVR was both non-inferior (pooled weighted proportion difference of -

36 g intravenous infusion of zoledronic acid is non-inferior, possibly more effective, and more acceptab

37 INTEREST established non-inferior survival of gefitinib compared with docetax

38 However, it has not been shown to be non inferior to current implantable cardioverter-defibri

39 terisation after repair of simple fistula is non-inferior to 14 day catheterisation and could be used

40 sh whether 7 day bladder catheterisation was non-inferior to 14 days in terms of incidence of fistula

41 Time to local progression with 4 Gy was not non-inferior to 24 Gy (hazard ratio 3.42, 95% CI 2.09-5.

42 60 Gy was non-inferior to 74 Gy (HR 0.84 [90% CI 0.68-1.03], pNI=0

43 fficacy of simplified three-dose regimens is non-inferior to a five-dose regimen.

44 n intensification provides glycaemic control non-inferior to a full basal-bolus regimen after 32 week

45 nib and methotrexate combination therapy was non-inferior to adalimumab and methotrexate combination

46 Dolutegravir has been shown to be non-inferior to an integrase inhibitor and superior to a

47 ethasone in combination with lenalidomide is non-inferior to and has lower toxicity than high-dose de

48 09, thus cisplatin plus gemcitabine was both non-inferior to and superior to paclitaxel plus gemcitab

49 EVG/COBI/FTC/TDF was non-inferior to ATV/RTV+FTC/TDF for the primary outcome

50 boosted lopinavir plus raltegravir would be non-inferior to boosted lopinavir plus NRTIs for virolog

51 BA was non-inferior to CBT (mITT: CBT 8.4 PHQ-9 points [SD 7.5]

52 nalysis of overall survival, panitumumab was non-inferior to cetuximab (Z score -3.19; p=0.0007).

53 Our findings show that panitumumab is non-inferior to cetuximab and that these agents provide

54 n 92% of previously untreated adults and was non-inferior to coformulated dolutegravir, abacavir, and

55 emtricitabine, and tenofovir alafenamide was non-inferior to continuing rilpivirine, emtricitabine, t

56 demand treatment with esomeprazole 20 mg was non-inferior to continuous maintenance treatment and red

57 Direct oral anticoagulants are non-inferior to conventional anticoagulants for the trea

58 radiotherapy using 60 Gy in 20 fractions is non-inferior to conventional fractionation using 74 Gy i

59 Rituximab (RTX) is non-inferior to cyclophosphamide (CYC) followed by azath

60 intravenous infusion of zoledronic acid was non-inferior to daily oral risedronate for prevention an

61 ent in bony defects in the esthetic zone was non-inferior to delayed implant placement after 1 year.

62 lacement with delayed provisionalization was non-inferior to delayed implant placement with delayed p

63 E/C/F/tenofovir alafenamide was non-inferior to E/C/F/tenofovir disoproxil fumarate, wit

64 +FTC and EFV+FTC-TDF were hypothesized to be non-inferior to EFV+3TC-ZDV if the upper one-sided 95% c

65 EVG/COBI/FTC/TDF was non-inferior to EFV/FTC/TDF; 305/348 (87.6%) versus 296/

66 Tofacitinib monotherapy was not shown to be non-inferior to either combination.

67 .8 min, 95% CI -97.2 to -24.4; p=0.0015) and non-inferior to entacapone (-26.2 min, -63.8 to 11.4; p=

68 he 10 mg twice daily dose of tofacitinib was non-inferior to etanercept 50 mg twice weekly and was su

69 INTERPRETATION: Rivaroxaban was non-inferior to fondaparinux for treatment of superficia

70 ondaparinux to assess whether rivaroxaban is non-inferior to fondaparinux in the prevention of thromb

71 HbA1c at 52 weeks, canagliflozin 100 mg was non-inferior to glimepiride (least-squares mean differen

72 luded that ICD insertion without testing was non-inferior to ICD with testing.

73 Initial treatment with rituximab is non-inferior to initial TNF inhibitor treatment in patie

74 IDegLira was non-inferior to insulin degludec (estimated treatment di

75 stablished whether sublingual misoprostol is non-inferior to intravenous oxytocin for treatment of po

76 inetic profile of subcutaneous rituximab was non-inferior to intravenous rituximab and was not associ

77 DP was non-inferior to IP with respect to the primary outcome,

78 Co-trimoxazole prophylaxis was non-inferior to IPTp with respect to infant mortality (r

79 OCT guidance was non-inferior to IVUS guidance (one-sided 97.5% lower CI

80 Ceftolozane-tazobactam was non-inferior to levofloxacin for composite cure (306 [76

81 ythmic drug treatment after cardioversion is non-inferior to long-term treatment.

82 INTERPRETATION: Ceftazidime-avibactam was non-inferior to meropenem in the treatment of nosocomial

83 Solithromycin was non-inferior to moxifloxacin in achievement of early cli

84 Gaviscon(R) was non-inferior to omeprazole in achieving a 24-h heartburn

85 Once-weekly dulaglutide is non-inferior to once-daily liraglutide for least-squares

86 ence 0.061 L [0.037 to 0.086]; p<0.0001) and non-inferior to open triple (-0.003L [-0.033 to 0.027];

87 her a cisplatin plus gemcitabine regimen was non-inferior to or superior to paclitaxel plus gemcitabi

88 Oral solithromycin was non-inferior to oral moxifloxacin for treatment of patie

89 ancer, survival with primary chemotherapy is non-inferior to primary surgery.

90 tion and dosing stability and was clinically non-inferior to PT monitoring.

91 It is hypothesized that bevacizumab is non-inferior to ranibizumab regarding its effectiveness.

92 However, if proved non-inferior to ranibizumab, use of the off-label bevaci

93 Our NtRTI-sparing regimen was non-inferior to standard treatment and represents a trea

94 ETATION: Starting patients on doxycycline is non-inferior to standard treatment with oral prednisolon

95 h lopinavir and ritonavir plus lamivudine is non-inferior to standard triple therapy.

96 was met, demonstrating that TAXUS Liberte is non-inferior to TAXUS Express.

97 and peginterferon alfa-2a and ribavirin was non-inferior to telaprevir and peginterferon alfa-2a and

98 e 1-infected previous non-responders and was non-inferior to telaprevir, thus providing an alternativ

99 ive HBV infection, tenofovir alafenamide was non-inferior to tenofovir disoproxil fumarate, and had i

100 in patients given subcutaneous rituximab was non-inferior to that in patients given intravenous ritux

101 Treatment of latent yaws was taken to be non-inferior to that of active yaws if the lower limit o

102 nd potent antiretroviral activity, which was non-inferior to that of efavirenz at week 48.

103 rile children managed by the e-POCT tool was non-inferior to that of febrile children managed by a va

104 V, the efficacy of tenofovir alafenamide was non-inferior to that of tenofovir disoproxil fumarate, a

105 se of the jet injector group was regarded as non-inferior to that of the needle and syringe group if

106 eous closure of the LAA with this device was non-inferior to that of warfarin therapy.

107 overall survival on intermittent therapy was non-inferior to that on continuous therapy, with a prede

108 .077, 95% CI -0.83 to -0.53) was similar and non-inferior to that with biaspart insulin (-0.76%, 0.07

109 DNA less than 29 IU/mL at week 48, which was non-inferior to the 195 (67%) of patients receiving teno

110 The study regimen was non-inferior to the control for virological rebound cumu

111 the bictegravir regimen was achieved and was non-inferior to the dolutegravir regimen in previously u

112 esorbable polymer sirolimus-eluting stent is non-inferior to the durable polymer everolimus-eluting s

113 imus-eluting bioabsorbable polymer stent was non-inferior to the everolimus-eluting durable polymer s

114 ccine given with the jet injector device was non-inferior to the immune response to influenza vaccine

115 every 4 weeks (-0.25 g/L, -1.79 to 1.29) was non-inferior to the mean change for patients who continu

116 en for severe malaria in African children is non-inferior to the more complex WHO-recommended regimen

117 chieve trough serum concentrations that were non-inferior to those achieved with intravenous rituxima

118 concentrations that were pharmacokinetically non-inferior to those achieved with intravenous rituxima

119 were to investigate whether indacaterol was non-inferior to tiotropium for trough forced expiratory

120 of -0.055 L, suggesting that indacaterol was non-inferior to tiotropium.

121 Dual therapy was classed as non-inferior to triple therapy if the lower bound of the

122 l once-daily tedizolid 200 mg for 6 days was non-inferior to twice-daily linezolid 600 mg for 10 days

123 Isavuconazole was non-inferior to voriconazole for the primary treatment o

124 e that ximelagatran has not been shown to be non-inferior to warfarin.

125 s 11.2% (12 of 107) for sham control (judged non-inferior, with a posterior probability of 1.00 [Baye